Becton Dickinson Shareholders: Ownership Structure, Brands, and Acquisition History
Last updated: November-2026Ownership Structure
Ownership Analysis
BD's ownership is public and institutionally influenced, with no controlling corporate parent. Common shareholders elect directors, while the board oversees management and group capital allocation. The approximately 6.60% Vanguard Capital Management and 5.90% BlackRock Fund Advisors positions reported in June 2026 illustrate substantial minority investment. Their authority concerns the shares held under their mandates, rather than direct operation of BD's manufacturing plants or clinical businesses.The February 2026 Waters transaction is the most important boundary to understand. BD distributed the separated Biosciences and Diagnostic Solutions business to its shareholders, and that business combined with Waters. The 39.2% fully diluted interest in the combined Waters company belonged to BD shareholders at closing. It was not a retained 39.2% corporate stake through which BD continued to control the transferred operations. Shared former ownership does not recreate a parent-subsidiary chain.BD received $4 billion in cash through the transaction and announced plans to divide it between share repurchases and debt reduction. That decision changed the capital structure supporting the retained medical-technology portfolio. We consider it a central exercise of board control because shareholders depend on directors to balance financial flexibility with investment in connected devices, manufacturing and quality. A distribution to owners is beneficial only when the remaining company can still meet its operating and strategic commitments.The retained group generated $19.457 billion of fiscal 2026 continuing revenue. Its control model must coordinate everyday consumables with complex systems such as Alaris, Pyxis and advanced monitoring. Those products share healthcare customers, but differ in development cycles and service requirements. We favor governance that makes the performance of each franchise visible while maintaining consistent quality standards. The separation creates clearer portfolio boundaries, but the value of that clarity will depend on execution and returns. Institutional ownership supplies oversight and capital, not a substitute for effective operating management.
Direct Owners
Institutional Shareholders
Shareholder Analysis
BD's shareholder register should be read with attention to both reporting dates and institutional entities. June 2026 data identifies Vanguard Capital Management at approximately 6.60% and BlackRock Fund Advisors at 5.90%. The annual proxy describes older group-level positions, including Vanguard and BlackRock, using different measurement dates. Adding all of those figures together would risk counting overlapping interests and exaggerating concentration within the register.The Waters distribution also created different possible investments for former BD-only holders. Eligible shareholders received approximately 0.135 Waters shares for each BD share held on the record date, with cash replacing fractional shares. They could subsequently retain both positions, sell one or alter their allocations independently. As a result, a shared investor base immediately after the transaction does not imply that BD controls Waters or that the two companies must continue with identical ownership patterns.Capital returns affected the retained BD investment as well. The company announced that $2 billion of transaction cash was intended for accelerated repurchases and $2 billion for debt repayment. Repurchases reduce shares outstanding when executed, which can alter percentage ownership even if an investor's absolute holding remains unchanged. We would therefore distinguish a stake measured before the program from a later percentage rather than attributing every increase to active stock buying.The main shareholder question is whether the focused medical-technology group earns better returns after separation. Fiscal 2026 continuing operating cash flow reached $3.6 billion, providing a meaningful reference for reinvestment and distributions. Investors should consider how much cash remains after manufacturing, technology and product-quality requirements. We see a broad institutional register as compatible with a long-term strategy, provided directors explain the economics clearly. The strongest evidence would be improved cash generation and dependable execution across retained franchises, rather than higher per-share earnings produced mainly through a shrinking denominator or comparisons with an unrecast historical portfolio.
Brands, Subsidiaries & Companies Owned
| Name | Type | Description |
|---|---|---|
| CareFusion | Subsidiary | Medication management and infusion technology operations acquired in 2015 |
| Alaris | Brand | Infusion systems and associated software |
| Pyxis | Brand | Automated medication management systems |
| BD Rowa | Brand | Pharmacy automation systems |
| Parata Systems | Subsidiary | Pharmacy automation company acquired in 2022 |
| C. R. Bard | Subsidiary | Interventional and surgical product operations acquired in 2017 |
| Phasix | Brand | Resorbable surgical mesh products |
| GalaFLEX | Brand | Soft tissue reinforcement scaffold products |
| Lutonix | Brand | Drug coated balloon technology |
| Bard PowerPort | Brand | Implantable vascular access ports |
| BD Advanced Patient Monitoring | Brand | Former Edwards Critical Care business acquired in 2024 |
| HemoSphere | Brand | Advanced hemodynamic monitoring platform |
| Swan-Ganz | Brand | Pulmonary artery catheter technology |
| FloTrac | Brand | Arterial waveform based hemodynamic monitoring technology |
| BD Vacutainer | Brand | Blood collection systems retained within medical essentials |
| BD Neopak | Brand | Prefillable syringe systems for pharmaceutical delivery |
Portfolio Analysis
BD's retained brands connect several stages of medication and hospital care. Alaris supplies infusion technology, Pyxis supports medication management and BD Rowa automates pharmacy workflows. The strategic attraction is the ability to address related operational problems across the hospital and pharmacy environment. However, each platform needs reliable integration and service. A broader catalog has limited value if customers must manage incompatible systems or inconsistent support.Bard adds a substantial interventional franchise, including vascular access, urology and surgical products. These businesses broaden BD's exposure beyond the traditional needle-and-syringe foundation while maintaining relationships with hospitals and specialist clinicians. Phasix and other surgical product families illustrate the move toward procedure-specific technologies. We see the best fit where BD can combine material expertise, manufacturing scale and established commercial access without diluting the clinical focus of the acquired operation.Advanced Patient Monitoring, acquired from Edwards for $4.2 billion in 2024, extends the group into monitoring and clinical decision support. Platforms such as HemoSphere and associated sensors add higher-technology components alongside consumables. Their economics depend on installed systems, recurring usage and the clinical usefulness of information delivered to care teams. That model differs from selling standardized supplies, so portfolio management needs to preserve the appropriate research, training and service capabilities.The Waters separation removed Biosciences and Diagnostic Solutions in February 2026. Those transferred operations, including their associated research and diagnostic platforms, should not be listed as retained BD brands. Continuing-operations revenue of $19.457 billion in fiscal 2026 describes the resulting portfolio more accurately than the old consolidated perimeter. We favor the strategic coherence of essential products linked to connected clinical workflows, but would judge success through adoption, reliability and cash returns. The new boundary makes it easier to evaluate whether the retained franchises reinforce one another economically, rather than merely sharing a corporate history and the BD name.
Market Share & Competitors
| Company | Market Share | Revenue | Key Strength |
|---|---|---|---|
| Medtronic | N/A | $36.3640B | Cardiovascular neuroscience and surgery FY2026 includes subsequently separated diabetes |
| Stryker | N/A | $25.1160B | Orthopedics surgical equipment and neurotechnology FY2025 |
| Boston Scientific | N/A | $20.0740B | Interventional cardiovascular and minimally invasive devices FY2025 |
| Becton Dickinson ★ | N/A | $19.4570B | Medication management consumables and intervention FY2026 continuing operations |
| Baxter International | N/A | $11.2440B | Infusion hospital supplies and connected care FY2025 continuing operations |
Competitive Analysis
BD competes across several medical-technology categories with very different purchasing dynamics. Baxter overlaps in infusion and hospital products, while other manufacturers compete in medication management, vascular access, surgery and patient monitoring. In standardized supplies, manufacturing quality and cost can be decisive. In connected systems and interventional devices, workflow integration, clinical evidence and service capability carry greater weight. A single global market-share number would conceal those differences.Fiscal 2026 continuing revenue of $19.457 billion gives BD substantial resources and commercial reach. That figure excludes the separated Biosciences and Diagnostic Solutions business, so comparisons with older company totals require the same perimeter. Waters is no longer simply a competitor or partner around a business BD still owns. It now houses the transferred operations following the February 2026 combination and has its own corporate governance and investment priorities.BD's strongest potential advantage lies in connecting routine products with higher-value hospital workflows. Pyxis, Alaris and pharmacy automation can become embedded in medication processes, while Bard products support specialist procedures. Advanced monitoring adds another layer of clinical information. We see these relationships as commercially useful when they reduce complexity or improve performance for customers. They provide less protection where buyers can switch equivalent consumables easily or where a competing technology produces better clinical or economic results.Execution is therefore central to the competitive case. Hospitals need dependable supply and systems that function safely within demanding care environments. Manufacturing or product-quality problems can undermine the benefit of a broad installed base. Continuing operating cash flow of $3.6 billion in fiscal 2026 indicates investment capacity, but cash must be deployed to maintain that reliability as well as to develop new products. We favor a competitive position based on consistent performance across defined franchises. The separation can sharpen focus, but BD must earn any resulting advantage through customer outcomes, service and cost discipline.
Acquisitions
| Company Acquired | Deal Value | Year | Description |
|---|---|---|---|
| CareFusion | $12.2B | 2015 | Announced cash and stock acquisition value |
| C. R. Bard | $24B | 2017 | Announced cash and stock transaction value |
| Venclose | undisclosed | 2021 | Venous disease treatment technology |
| Parata Systems | $1.548B | 2022 | Total cash consideration reported in fiscal 2022 annual report |
| Edwards Critical Care | $4.2B | 2024 | All cash acquisition renamed BD Advanced Patient Monitoring |
Acquisitions Analysis
BD's major acquisitions have progressively shifted the group from a predominantly consumables business toward a broader medical-technology portfolio. CareFusion's 2015 acquisition, announced at $12.2 billion, brought medication-management and infusion platforms. Bard's 2017 acquisition, announced at approximately $24 billion, added substantial interventional capabilities. These were strategic changes in the type of products and clinical workflows BD could address, rather than simple additions to manufacturing volume.The 2024 acquisition of Edwards Lifesciences' Critical Care business for $4.2 billion continued that shift. Renamed Advanced Patient Monitoring, it added monitoring systems, sensors and decision-support capabilities. We see a plausible relationship to connected care because useful patient information can complement medication delivery and hospital workflows. The economic case still depends on customers adopting the technology and recurring products, rather than the acquisition automatically creating cross-selling benefits across every BD account.Smaller purchases, including Parata in pharmacy automation and technology additions in vascular intervention, supplement those larger platforms. The pattern is most attractive when a new capability strengthens an existing clinical workflow and can use BD's commercial reach. It is less persuasive when integration demands or development costs overwhelm the advantage of adding another product family. Purchase prices therefore need to be assessed together with the capital required after closing.The February 2026 Waters separation provides an important counterweight to acquisition-led expansion. BD transferred a major business outside the group while retaining the more focused medical-technology portfolio. We would evaluate future deals against that stated direction, rather than rewarding scale for its own sake. Approximately $19.5 billion of fiscal 2026 continuing revenue gives the company resources, but also a sizable installed business requiring attention. The strongest acquisition discipline would preserve balance-sheet flexibility, strengthen product quality and generate returns exceeding the alternative of internal development or shareholder distributions. Historical transaction size alone cannot establish whether the retained businesses now earn adequate returns.
Acquisition Timeline
Merger & Spin-off History
Merger & Spin-off Analysis
BD's recent history combines large acquisitions with deliberate separations. CareFusion in 2015 added medication-management infrastructure, and Bard in 2017 expanded interventional products. The announced values of $12.2 billion and approximately $24 billion show how much capital the company committed to building a broader medical-technology group. Those combinations shaped the retained portfolio, while also increasing the importance of integration, debt capacity and clear operating accountability.The 2022 diabetes-care spin-off created embecta as an independent company. That event removed an established business from BD rather than selling the entire parent to another owner. Eligible shareholders received a separate investment, allowing the two companies to pursue different priorities. We consider this an early indication that BD's strategy included removing businesses as well as buying them, even when the separated operations had a long association with its corporate name.The February 2026 Biosciences and Diagnostic Solutions transaction was more complex. BD spun off the business and combined it with Waters. Shareholders received approximately 0.135 Waters shares per BD share, and their initial interest represented 39.2% of the combined company on a fully diluted basis. BD itself received $4 billion in cash. The distributed equity belonged to shareholders, making it incorrect to treat Waters as a partially owned BD subsidiary afterward.We see the transaction as a substantial change in the portfolio's economic character. The retained company concentrates on medical technology, while shareholders can hold the separated scientific and diagnostic exposure through Waters if they choose. Fiscal 2026 results present continuing operations separately, enabling a more useful assessment of the remaining business. The shareholder test is whether sharper focus and a revised capital structure compensate for separation costs and the loss of shared resources. A successful transaction should improve investment choices and execution in the retained franchises, rather than simply produce a different organizational chart or a larger repurchase announcement.
Ownership History
Ownership History Analysis
BD originated in 1897 through the partnership of Maxwell Becton and Fairleigh Dickinson. The company built its reputation around medical products and gradually expanded internationally. Public ownership, established through its 1962 listing, broadened the investor base beyond the founders' original interests. Today's company is governed by a board accountable to common shareholders, rather than a founding-family majority or a controlling industrial parent.The register evolved as the business expanded and issued equity in major combinations. CareFusion and Bard added large operating portfolios, with consideration that included BD shares as well as cash. Those transactions changed both what existing investors owned and the capital structure financing the group. We regard that dilution as economically justified only to the extent that the acquired businesses subsequently earned returns above the capital committed to them.The 2022 embecta spin-off and 2026 Waters combination changed shareholder exposure through distributions rather than another expansion of the same parent. The Waters transaction gave eligible BD investors a separate equity interest while transferring Biosciences and Diagnostic Solutions outside the group. BD received $4 billion in cash, but did not retain the 39.2% Waters position distributed to shareholders. That distinction explains why the current ownership tree ends in BD's investors rather than extending through Waters as an owned subsidiary.June 2026 data lists Vanguard Capital Management at approximately 6.60% and BlackRock Fund Advisors at 5.90%, reflecting the prominence of institutional capital in the contemporary register. The company generated $19.457 billion of continuing revenue in fiscal 2026. We see the ownership history as a transition from founder-led medical supplies to a publicly financed, actively managed technology portfolio. Its present value depends on how effectively the board allocates capital across retained platforms. The founders' names and older acquisition histories explain the business, but cannot substitute for a clear view of the assets and liabilities shareholders actually own after separation.
Ownership Explained
Becton Dickinson, commonly known as BD, is a global medical-technology company founded in 1897 and headquartered in Franklin Lakes, New Jersey. Its NYSE-listed shares trade as BDX. The group provides medication delivery, pharmacy automation, vascular access, interventional products and patient monitoring technologies. It operates independently, with public shareholders owning the parent and no corporate majority owner. The stock market valued its equity at approximately $58.47 billion on November 10, 2026.Investment managers hold substantial minority interests. June 2026 ownership data identifies Vanguard Capital Management at approximately 6.60% and BlackRock Fund Advisors at 5.90%. The annual proxy also describes earlier group-level holdings, whose dates and reporting scope differ from the newer positions. Those investment interests provide shareholder voting influence. They do not make BD an operating subsidiary of Vanguard, BlackRock or a hospital customer.BD's current portfolio differs materially from its historical three-segment group. On February 9, 2026, it completed the spin-off of Biosciences and Diagnostic Solutions and that business's combination with Waters. BD shareholders received Waters shares, while BD received $4 billion in cash. The parent does not own the 39.2% Waters interest distributed to its shareholders. Platforms transferred in that transaction should therefore be excluded from BD's retained subsidiaries and brands.Retained operations include Alaris infusion systems, Pyxis medication management, BD Rowa pharmacy automation, Bard interventional products and the Advanced Patient Monitoring business acquired from Edwards Lifesciences. Fiscal 2026 continuing-operations revenue was $19.457 billion, and continuing operating cash flow reached $3.6 billion. We see the new portfolio as a more focused combination of essential consumables, connected medication systems and intervention technologies. The strategic opportunity lies in connecting reliable everyday products with higher-value clinical workflows. Shareholder returns depend on product quality, manufacturing execution and disciplined reinvestment after the major separation, rather than assuming the historical diagnostic businesses remain part of today's company.
BDX shareholders own BD's retained medical-technology operations. Eligible shareholders also received a separate Waters investment through the February 2026 distribution. Their direct Waters holdings are distinct from BD's own assets and do not mean Waters became a BD subsidiary.Hospitals continue purchasing retained platforms such as Alaris, Pyxis and Bard products from the BD group. Corporate investment and product-quality oversight remain responsibilities of BD's management and board under public shareholder governance.